Recent Articles
DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more
AT A GLANCE DaVita Inc. issued a statement in response to Novo Nordisk in relation ‘…to its FLOW study that sought to demonstrate that Ozempic delays progression of...
Read MoreCompounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day.
Hello all, It continues to be a fascinating, rapid and intense period of development in obesity and metabolic medicine. We learn something new virtually every...
Read MoreNovo Nordisk’s huge windfall; employers scramble to keep a lid on rising health care spending;
Hello all, I hope everyone is having a wonderful weekend. I am back home after an intense week on the road, capped by a terrific...
Read MoreRisks of intestinal blockage, suicide and pneumonia with GLP-1 meds; racial, social and economic inequities
Hello Friends, Welcome to October. It has been an extraordinarily busy period here at twenty30 health; amongst many other activities and initiatives, yours’ truly has...
Read MoreOprah & Ozempic; inevitable GLP-1 plateaus; record medical interest in obesity; compounded med controversy; pharma-based
Hello everyone, I hope you are well. We have some quite interesting news pieces this week, including reporting on Eli Lilly’s lawsuits against compounding pharmacies;...
Read MoreOver 70 companies in the obesity medications race; a new business model for weight management;
Hello everyone, I hope you are enjoying this weekend, one where — at least in much of the US Northeast — the weather is feeling...
Read More